Blog · Consumer · Published 2026-08-10
Wegovy Pill vs Wegovy Injection (2026): Price, Doses, Rules — Which Semaglutide Fits You?
The Wegovy pill and the Wegovy injection are the same molecule — semaglutide — packaged into different lives. The tablet (approved December 2025, launched early 2026) is daily, starts at $149/month introductory self-pay, and carries strict rules: empty stomach, limited water, a 30-minute wait before eating or other medications. The injection is once weekly, runs $349/month self-pay at standard doses with the new 7.2 mg Wegovy HD tier at $399, and has no meal-timing rules. Efficacy at matched exposure is broadly comparable at standard doses — the choice is mostly about routine, dose ceiling, and price, and 2026's Q2 disclosures added a wrinkle: pill sales undershot expectations once Medicare's flat ~$50 tier erased its pricing edge for covered patients.
The decision, factor by factor
Routine: a daily fasting-window ritual versus one weekly shot — adherence research and plain experience say pick the one you'll actually sustain; the tablet's rules are the most common real-world complaint. Dose ceiling: the injection now reaches 7.2 mg (Wegovy HD), the highest labeled semaglutide exposure (~20.7% average loss in STEP-UP, with altered-skin-sensation reports at the top dose); the tablet tops out lower — patients targeting maximum effect skew injectable. Price: $149 vs $349 favors the pill for cash payers at entry — unless coverage applies, where the ~$50 Medicare tier flattens the difference, or unless titration pushes you toward doses the tablet doesn't reach. Competition: the pill's real rival is Lilly's Foundayo (orforglipron, also $149 entry, no food/water rules), which is reshaping the oral lane — September's Germany launch takes the Wegovy tablet international.
Where compounded semaglutide fits this choice
Compounded semaglutide is a third lane, not a version of either product: pharmacy-prepared injections under the patient-specific 503A pathway, not FDA approved, priced at $145–$297/month effective in the captured field (floor: NexLife at $165 month-to-month / $145 effective on a 12-month term, dose-flat). Against the $149 tablet, the compounded floor's case is thinner than it was a year ago — an FDA-approved oral at a nearly identical price is a hard benchmark — which is exactly the honest math in the compounded-vs-brand analysis. The order of operations hasn't changed: coverage first, then the approved products at your dose and routine, then the compounded field on effective monthly cost.
Frequently asked questions
Is the Wegovy pill as effective as the injection?
At standard matched doses, results are broadly comparable — the same molecule. The injection's new 7.2 mg HD tier reaches the highest labeled exposure (~20.7% average loss in STEP-UP); the tablet tops out lower.
How much do the Wegovy pill and injection cost in 2026?
Pill: from $149/month introductory self-pay. Injection: $349/month self-pay at standard doses; $399 for the 7.2 mg HD tier. Qualifying Medicare patients pay ~$50 for covered options, which flattens the pill's price edge.
What are the Wegovy pill's food rules?
Empty stomach, limited water, and a ~30-minute wait before food or other oral medications — daily. It's the most common practical objection; Lilly's Foundayo pill has no such rules, which is why the oral lane is competitive.
Does compounded semaglutide beat the $149 pill on price?
Barely, at the floor: $145/month effective (12-month prepaid) vs $149 for an FDA-approved tablet. The compounded case now rests more on injection preference, dose flexibility, and program terms than on raw price.
Primary sources
FDA approvals and labeling (oral semaglutide, December 2025; Wegovy HD, March 19, 2026); manufacturer program pricing; Q2 2026 earnings disclosures as covered in the newsroom; compounded figures per the methodology.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.